Vnitr Lek 2016, 62(4):246-247

Populace pacientů s diabetem se změnila, pacienti žijí déle a vykazují vyšší riziko srdečního selhání - editorial

Milan Kvapil
Interní klinika 2. LF UK a FN v Motole, Praha

Received: April 11, 2016; Published: April 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kvapil M. Populace pacientů s diabetem se změnila, pacienti žijí déle a vykazují vyšší riziko srdečního selhání - editorial. Vnitr Lek. 2016;62(4):246-247.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Brož J, Honěk P, Dušek L et al. The mortality of patients with diabetes mellitus using oral antidiabetic drugs in the Czech Republic decreased over the decade of 2003-2013 and came closer to the population average. Vnitř Lék 2015; 61(11 Suppl 3): 3S14-3S20.
    2. Kvapil M. Realistic possibilities of using data sources in quality assessment of care of patients with diabetes in the Czech Republic: National Diabetes Information System. Vnitř Lék 2015; 61(11 Suppl 3): 3S10-3S13.
    3. Aneja A, Tang WH, Bansilal S et al. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 2008; 121(9): 748-757. Go to original source... Go to PubMed...
    4. Nichols GA, Koro CE, Gullion CM et al. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 2005; 21(1): 51-57. Go to original source... Go to PubMed...
    5. Sonesson C et al. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol 2016; 15(1): 37. Go to original source... Go to PubMed...
    6. Zinman B, Wanner C, Lachin JM et al. [EMPA-REG OUTCOME Investigators]. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117-2128. Go to original source... Go to PubMed...
    7. Kvapil M. EMPA REG OUTCOME. Důkaz, že populace pacientů s diabetem se mění. Remedia 2016; 26(1): 67-72.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.